<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38806438</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of hyperbaric oxygen therapy for long COVID: a protocol for systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e083868</StartPage><MedlinePgn>e083868</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e083868</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-083868</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">There is still a lack of therapeutic options for long COVID. Several studies have shown the benefit of hyperbaric oxygen therapy (HBOT) on long COVID. However, the efficacy and safety of HBOT for long COVID remain unclear. Therefore, we will conduct this systematic review to assess the feasibility of HBOT as a primary or complemental therapy for long COVID.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">Databases such as Web of Science, PubMed, Embase, Cochrane Database of Systematic Reviews, ClinicalTrials.gov, International Clinical Trials Registry Platform, Wanfang Database, China National Knowledge Infrastructure, SINOMED, VIP Database and the Chinese Clinical Trial Registry will be searched systematically from the establishment to 9 December 2023. All articles will be reviewed by two independent reviewers. Cochrane risk of bias tool will be used to assess the risk of bias in the study. We will evaluate heterogeneity using a visual inspection of the funnel plot. If an available number of studies are identified, we will perform a meta-analysis.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">No ethical approval is required since this study is based on published articles. The findings will be published in a peer-reviewed journal or disseminated through conference presentations.</AbstractText><AbstractText Label="PROSPERO REGISTRATION NUMBER" NlmCategory="UNASSIGNED">CRD42023482523.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0000-2874-1861</Identifier><AffiliationInfo><Affiliation>Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jingnan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jiazhu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuntao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhongde</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Emergency, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China doctorzzd99@gzucm.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="Y">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Post-Acute COVID-19 Syndrome</Keyword><Keyword MajorTopicYN="N">Public health</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38806438</ArticleId><ArticleId IdType="pmc">PMC11138265</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-083868</ArticleId><ArticleId IdType="pii">bmjopen-2024-083868</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023;21:133&#x2013;46. 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, et al. . Long Covid: where we stand and challenges ahead. Cell Death Differ 2022;29:1891&#x2013;900. 10.1038/s41418-022-01052-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-01052-6</ArticleId><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;7. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med 2023;29:2347&#x2013;57. 10.1038/s41591-023-02521-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02521-2</ArticleId><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M, Ciciarello F, Zazzara MB, et al. . Nutraceuticals and dietary supplements for older adults with long COVID-19. Clin Geriatr Med 2022;38:565&#x2013;91. 10.1016/j.cger.2022.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9212635</ArticleId><ArticleId IdType="pubmed">35868674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, et al. . Serotonin reduction in post-acute sequelae of viral infection. Cell 2023;186:4851&#x2013;67. 10.1016/j.cell.2023.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C, Br&#xfc;ningk SC, Hoch T, et al. . Persistent complement dysregulation with signs of Thromboinflammation in active long Covid. Science 2024;383:eadg7942. 10.1126/science.adg7942</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman B, Charlton BT, Goulding RP, et al. . Muscle abnormalities worsen after post-Exertional malaise in long COVID. Nat Commun 2024;15:17. 10.1038/s41467-023-44432-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44432-3</ArticleId><ArticleId IdType="pmc">PMC10766651</ArticleId><ArticleId IdType="pubmed">38177128</ArticleId></ArticleIdList></Reference><Reference><Citation>Boufidou F, Medi&#x107; S, Lampropoulou V, et al. . SARS-Cov-2 Reinfections and long COVID in the post-Omicron phase of the pandemic. Int J Mol Sci 2023;24:12962. 10.3390/ijms241612962</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241612962</ArticleId><ArticleId IdType="pmc">PMC10454552</ArticleId><ArticleId IdType="pubmed">37629143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C-C, Hsu C-K, Yen M-Y, et al. . Long COVID: an inevitable Sequela of SARS-Cov-2 infection. J Microbiol Immunol Infect 2023;56:1&#x2013;9. 10.1016/j.jmii.2022.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.10.003</ArticleId><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="pubmed">36283919</ArticleId></ArticleIdList></Reference><Reference><Citation>Akarsu S, Tekin L, Ay H, et al. . The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome. Undersea Hyperb Med 2013;40:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">23682549</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvert M, Kyte D, Mercieca-Bebber R, et al. . Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 2018;319:483&#x2013;94. 10.1001/jama.2017.21903</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.21903</ArticleId><ArticleId IdType="pubmed">29411037</ArticleId></ArticleIdList></Reference><Reference><Citation>Oscarsson N, M&#xfc;ller B, Ros&#xe9;n A, et al. . Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol 2019;20:1602&#x2013;14. 10.1016/S1470-2045(19)30494-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30494-2</ArticleId><ArticleId IdType="pubmed">31537473</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T, Gonevski M, Clark C, et al. . Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clinical Medicine 2021;21:e629&#x2013;32. 10.7861/clinmed.2021-0462</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2021-0462</ArticleId><ArticleId IdType="pmc">PMC8806311</ArticleId><ArticleId IdType="pubmed">34862223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zant AE, Figueroa XA, Paulson CP, et al. . Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms. Undersea Hyperb Med 2022;49:333&#x2013;9. 10.22462/05.06.2022.7</Citation><ArticleIdList><ArticleId IdType="doi">10.22462/05.06.2022.7</ArticleId><ArticleId IdType="pubmed">36001566</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrakic-Sposta S, Vezzoli A, Garetto G, et al. . Hyperbaric oxygen therapy counters oxidative stress/inflammation-driven symptoms in long COVID-19 patients: preliminary outcomes. Metabolites 2023;13:1032. 10.3390/metabo13101032</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo13101032</ArticleId><ArticleId IdType="pmc">PMC10608857</ArticleId><ArticleId IdType="pubmed">37887357</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, et al. . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647. 10.1136/bmj.g7647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7647</ArticleId><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Moher D, Bossuyt PM, et al. . PRISMA 2020 explanation and elaboration: updated guidance and Exemplars for reporting systematic reviews. BMJ 2021;372:160. 10.1136/bmj.n160</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n160</ArticleId><ArticleId IdType="pmc">PMC8005925</ArticleId><ArticleId IdType="pubmed">33781993</ArticleId></ArticleIdList></Reference><Reference><Citation>Beets MW, Weaver RG, Ioannidis JPA, et al. . Influence of pilot and small trials in meta-analyses of behavioral interventions: a meta-Epidemiological study. Syst Rev 2023;12:21. 10.1186/s13643-023-02184-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02184-7</ArticleId><ArticleId IdType="pmc">PMC9938611</ArticleId><ArticleId IdType="pubmed">36803891</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi SAR, Thalib L. A quality-effects model for meta-analysis. Epidemiology 2008;19:94&#x2013;100. 10.1097/EDE.0b013e31815c24e7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e31815c24e7</ArticleId><ArticleId IdType="pubmed">18090860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F, Efstathiou C, Openshaw PJM. Long COVID: clues about causes. Eur Respir J 2023;61:2300409. 10.1183/13993003.00409-2023</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00409-2023</ArticleId><ArticleId IdType="pmc">PMC10040855</ArticleId><ArticleId IdType="pubmed">36958743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. . Long Covid outcomes at one year after mild SARS-Cov-2 infection: nationwide cohort study. BMJ 2023;380:e072529. 10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of Postacute sequelae of SARS-Cov-2 infection: A systematic review. JAMA Netw Open 2021;4:e2128568. 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Almzaiel AJ, Billington R, Smerdon G, et al. . Effects of hyperbaric oxygen treatment on antimicrobial function and apoptosis of differentiated HL-60 (neutrophil-like) cells. Life Sci 2013;93:125&#x2013;31. 10.1016/j.lfs.2013.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2013.06.003</ArticleId><ArticleId IdType="pubmed">23770209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolde SD, Hulskes RH, Weenink RP, et al. . The effects of hyperbaric oxygenation on oxidative stress. Inflammation and Angiogenesis Biomolecules 2021;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394403</ArticleId><ArticleId IdType="pubmed">34439876</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner I, Shephard RJ, Shek PN. Immune function in hyperbaric environments, diving, and decompression. Undersea Hyperb Med 1999;26:27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10353182</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcinkowska AB, Mankowska ND, Kot J, et al. . Impact of hyperbaric oxygen therapy on cognitive functions: a systematic review. Neuropsychol Rev 2022;32:99&#x2013;126. 10.1007/s11065-021-09500-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-021-09500-9</ArticleId><ArticleId IdType="pmc">PMC8888529</ArticleId><ArticleId IdType="pubmed">33847854</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, You J, Ma H, et al. . Efficacy and safety of hyperbaric oxygen therapy for Fibromyalgia: a systematic review and meta-analysis. BMJ Open 2023;13:e062322. 10.1136/bmjopen-2022-062322</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062322</ArticleId><ArticleId IdType="pmc">PMC9872467</ArticleId><ArticleId IdType="pubmed">36690401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Hassler A, Bostr&#xf6;m E, et al. . Hyperbaric oxygen therapy for long COVID (HOT-Loco), an interim safety report from a randomised controlled trial. BMC Infect Dis 2023;23:33. 10.1186/s12879-023-08002-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08002-8</ArticleId><ArticleId IdType="pmc">PMC9854077</ArticleId><ArticleId IdType="pubmed">36670365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega MA, Fraile-Martinez O, Garcia-Montero C, et al. . A general overview on the hyperbaric oxygen therapy: applications. Mechanisms and Translational Opportunities Medicina (Kaunas) 2021;57. 10.3390/medicina57090864</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57090864</ArticleId><ArticleId IdType="pmc">PMC8465921</ArticleId><ArticleId IdType="pubmed">34577787</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>